Literature DB >> 16456815

Nuclear expression of the antiapoptotic protein survivin in malignant melanoma.

Yiling Ding1, Victor G Prieto, Peter S Zhang, Seth Rosenthal, Kathleen J Smith, Henry G Skelton, A Hafeez Diwan.   

Abstract

BACKGROUND: Expression of the antiapoptotic protein survivin has been demonstrated in some melanocytic lesions and is believed to be required for melanoma cell viability. However, its diagnostic value in differentiating melanomas from nevi has not yet been examined.
METHODS: Tissue microarray blocks were constructed with paraffin-fixed tissue of 19 nevi, 18 dysplastic nevi, 24 malignant melanomas, and 31 metastatic melanomas. Sections were then reacted with three antisurvivin antibodies (two monoclonal and one polyclonal) assessing labeling intensity (absent or weak, and moderate to strong) as well as the percentage of cells labeled (< 25%, > or = 25%).
RESULTS: Of the antibodies evaluated, the polyclonal one was found to be the most sensitive. Nuclear immunoreactivity for survivin (i.e., > or = 25% of cells exhibiting and/or at least moderately intense staining) was seen in a subset of melanomas but not in nevi or dysplastic nevi (P < 0.05).
CONCLUSIONS: Survivin is variably expressed in the cytoplasm in the entire spectrum of melanocytic lesions, with nuclear expression detectable only in melanomas. These data may underscore the importance of nuclear survivin in progression to melanoma and may prove useful in the differential diagnosis of melanoma versus nevus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16456815     DOI: 10.1002/cncr.21727

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Apoptosis and injuries of heavy ion beam and x-ray radiation on malignant melanoma cell.

Authors:  Jin Qin; Sha Li; Chao Zhang; Dong-Wei Gao; Qiang Li; Hong Zhang; Xiao-Dong Jin; Yang Liu
Journal:  Exp Biol Med (Maywood)       Date:  2017-01-01

Review 2.  Immune-phenotypical markers for the differential diagnosis of melanocytic lesions.

Authors:  Gerardo Botti; Laura Marra; Annamaria Anniciello; Giosuè Scognamiglio; Vincenzo Gigantino; Monica Cantile
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

3.  Relation between expression pattern of p53 and survivin in cutaneous basal cell carcinomas.

Authors:  Marian Adamkov; Erika Halasova; Julius Rajcani; Marian Bencat; Desanka Vybohova; Silvia Rybarova; Stefan Galbavy
Journal:  Med Sci Monit       Date:  2011-02-25

Review 4.  Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin.

Authors:  Ronan J Kelly; Ariel Lopez-Chavez; Deborah Citrin; John E Janik; John C Morris
Journal:  Mol Cancer       Date:  2011-04-06       Impact factor: 27.401

5.  Evaluation of survivin splice variants in pituitary tumors.

Authors:  Joanna Waligórska-Stachura; Mirosław Andrusiewicz; Nadia Sawicka-Gutaj; Marta Kubiczak; Anna Jankowska; Włodzimierz Liebert; Agata Czarnywojtek; Ryszard Waśko; Al Ricardo Blanco-Gangoo; Marek Ruchała
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

Review 6.  Survivin-Based Treatment Strategies for Squamous Cell Carcinoma.

Authors:  Andrea Santarelli; Marco Mascitti; Lucio Lo Russo; Davide Sartini; Giuseppe Troiano; Monica Emanuelli; Lorenzo Lo Muzio
Journal:  Int J Mol Sci       Date:  2018-03-24       Impact factor: 5.923

7.  Development of a carrier system containing hyaluronic acid and protamine for siRNA delivery in the treatment of melanoma.

Authors:  Jing Yang; Rong Zhao; Qun Feng; Xuequn Zhuo; Rui Wang
Journal:  Invest New Drugs       Date:  2020-08-13       Impact factor: 3.850

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.